RxDoctor Payments Data

Anupama Kale, MD

Neurology · Amherst, NYNPI 1467765784

Payments from drug & device makers

$393,622in general payments, 2019–2025

Across 1,124 payments — averaging $350.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$162K
  • Genentech, Inc.$117K
  • AbbVie$47K
  • Neurocrine Biosciences, Inc.$22K
  • MDD US Operations, LLC$12K
  • Amneal Pharmaceuticals LLC$8K
  • plus $26K from 54 others

What the payments were for

  • Consulting fees$16,27524%
  • Speaking & faculty fees$25,02836%
  • Travel & lodging$4,2026%
  • Food & beverage$20,65030%
  • Education$2,6264%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurology Practice Consortium GPO, LLC6$162,425
Genentech, Inc.14$117,431
AbbVie(2 entities)83$46,546
Neurocrine Biosciences, Inc.84$21,594
MDD US Operations, LLC62$11,583
Amneal Pharmaceuticals LLC89$7,786
Adamas Pharmaceuticals, Inc.19$6,692
Kyowa Kirin, Inc.24$3,725
UCB, Inc.56$1,196
Sunovion Pharmaceuticals Inc.6$1,004
Teva Pharmaceuticals USA, Inc.53$1,004
Novartis68$877
Jazz Pharmaceuticals Inc.15$860
Medtronic(2 entities)7$768
AstraZeneca(2 entities)42$747
Avanir Pharmaceuticals, Inc.25$578
Acadia Pharmaceuticals Inc44$552
Abbott16$508
Tanabe Pharma America, Inc.30$483
Alnylam Pharmaceuticals Inc.26$442
Amgen(2 entities)15$441
Lundbeck LLC22$421
SK Life Science, Inc.19$375
Acorda Therapeutics, Inc8$307
GE HealthCare32$298
Johnson & Johnson(2 entities)18$288
Pfizer16$287
Catalyst Pharmaceuticals, Inc.11$260
Otsuka America Pharmaceutical, Inc.14$250
Biohaven Pharmaceutical Holding Company Ltd.15$228
Mallinckrodt Hospital Products Inc.7$204
Biogen10$194
Supernus Pharmaceuticals, Inc.11$187
TG Therapeutics, Inc.9$169
Merz Pharmaceuticals, LLC7$151
Livanova USA, Inc.7$149
CSL Behring7$146
Revance Therapeutics, Inc.1$140
Grifols USA, LLC7$133
Axsome Therapeutics, Inc.7$133
Lilly USA, LLC7$126
Banner Life Sciences, LLC8$118
Upsher-smith Laboratories LLC7$115
Eisai Inc.5$104
Azurity Pharmaceuticals, Inc.6$102
Inspire Medical Systems, Inc.1$102
Harmony Biosciences LLC5$102
Arbor Pharmaceuticals, Inc.5$92
Sanofi7$91
Takeda Pharmaceuticals U.S.A., Inc.4$73
Ipsen Biopharmaceuticals, Inc4$71
Sanofi-aventis U.S. LLC3$68
Akcea Therapeutics, Inc.4$67
Bristol Myers Squibb4$66
Merz North America, Inc.2$62
Greenwich Biosciences, Inc.4$58
Avion Pharmaceuticals4$55
Impel Pharmaceuticals LLC2$52
Vanda Pharmaceuticals Inc.3$52
Boston Scientific2$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393,622 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$885,915
Medicare patients
306
Services billed
39,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate30$233,595
GocovriAmantadine Hcl34$104,922
RytaryCarbidopa/Levodopa51$86,378
InbrijaLevodopa18$67,075
NuplazidPimavanserin Tartrate12$59,465
Carbidopa-LevodopaCarbidopa/Levodopa1,089$43,416
NourianzIstradefylline12$21,981
OngentysOpicapone21$19,492
Carbidopa44$13,014
Rasagiline Mesylate72$11,643
Primidone331$8,091
Propranolol Hcl ErPropranolol Hcl154$3,804
Rivastigmine39$3,469
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone18$3,388
RivastigmineRivastigmine Tartrate60$3,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$21,594$253,08751 claims
MDD US Operations, LLCGocovri$11,583$104,92234 claims
Amneal Pharmaceuticals LLCRytary$7,786$86,37851 claims
Acorda Therapeutics, IncInbrija$307$67,07518 claims
Acadia Pharmaceuticals IncNuplazid$552$59,46512 claims
Kyowa Kirin, Inc.Nourianz$3,725$21,98112 claims
Upsher-smith Laboratories LLCTopiramate$115$81091 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →